Table 2. Seropositivity of polyomaviruses and association with lung cancer.
|
Cases |
Controls |
|||||
|---|---|---|---|---|---|---|
| n | % | n | % | Odds ratio (95% CI) | P-value | |
| JCV (VP1) | 353 | 69.1 | 349 | 68.7 | 1.02 (0.78–1.33) | 0.90 |
| JCV (VP1±TAg) | 368 | 72.0 | 363 | 71.5 | 1.03 (0.78–1.35) | 0.84 |
| BKV (VP1) | 455 | 89.0 | 456 | 89.8 | 0.93 (0.62–1.38) | 0.71 |
| BKV (VP1±TAg) | 455 | 89.0 | 456 | 89.8 | 0.93 (0.62–1.38) | 0.71 |
| KI (VP1) | 434 | 84.9 | 445 | 87.6 | 0.80 (0.56–1.14) | 0.22 |
| WU (VP1) | 490 | 95.9 | 492 | 96.9 | 0.76 (0.39–1.47) | 0.41 |
| TSV (VP1) | 391 | 76.5 | 387 | 76.2 | 1.02 (0.76–1.36) | 0.90 |
| TSV (VP1±TAg) | 392 | 76.7 | 388 | 76.4 | 1.02 (0.76–1.36) | 0.13 |
| MCV (VP1) | 303 | 59.3 | 313 | 61.6 | 0.91 (0.71–1.17) | 0.45 |
| MCV (VP1±small TAg±large TAg) | 305 | 59.7 | 314 | 61.8 | 0.91 (0.71–1.18) | 0.49 |
| HPyV6 (VP1) | 393 | 76.9 | 399 | 78.5 | 0.91 (0.68–1.22) | 0.53 |
| HPyV6 (VP1±TAg) | 393 | 76.9 | 400 | 78.7 | 0.90 (0.67–1.21) | 0.48 |
| HPyV7 (VP1) | 330 | 64.6 | 332 | 65.4 | 0.97 (0.75–1.25) | 0.80 |
| HPyV7 (VP1±TAg) | 333 | 65.2 | 334 | 65.8 | 0.97 (0.75–1.26) | 0.85 |
| HPyV10 (VP1) | 492 | 96.3 | 496 | 97.6 | 0.63 (0.30–1.30) | 0.21 |
| HPyV10 (VP1±TAg) | 492 | 96.3 | 497 | 97.8 | 0.57 (0.27–1.22) | 0.15 |
|
Analysis including adenocarcinoma only | ||||||
| JCV (VP1) | 207 | 69.5 | 196 | 66.7 | 1.14 (0.80–1.61) | 0.47 |
| JCP (VP1±TAg) | 216 | 72.5 | 204 | 69.4 | 1.16 (0.81–1.66) | 0.41 |
| BKV (VP1) | 265 | 88.9 | 268 | 91.2 | 0.78 (0.45–1.34) | 0.37 |
| BKV (VP1±TAg) | 265 | 88.9 | 268 | 91.2 | 0.78 (0.45–1.34) | 0.37 |
| KI (VP1) | 251 | 84.3 | 258 | 87.8 | 0.75 (0.47–1.19) | 0.22 |
| WU (VP1) | 285 | 95.6 | 287 | 97.6 | 0.53 (0.21–1.36) | 0.19 |
| TSV (VP1) | 230 | 77.2 | 219 | 74.5 | 1.16 (0.79–1.69) | 0.44 |
| TSV (VP1±TAg) | 230 | 77.2 | 220 | 74.8 | 1.14 (0.78–1.66) | 0.5 |
| MCV (VP1) | 162 | 54.4 | 184 | 62.6 | 0.71 (0.51–0.99) | 0.04 |
| MCV (VP1±small TAg±large TAg) | 163 | 54.7 | 184 | 62.6 | 0.72 (0.52–1.00) | 0.05 |
| HPyV6 (VP1) | 226 | 75.8 | 239 | 81.3 | 0.72 (0.49–1.07) | 0.11 |
| HPyV6 (VP1±TAg) | 226 | 75.8 | 240 | 81.6 | 0.71 (0.47–1.05) | 0.09 |
| HPyV7 (VP1) | 188 | 63.1 | 204 | 69.4 | 0.75 (0.54–1.06) | 0.11 |
| HPyV7 (VP1±TAg) | 190 | 63.8 | 205 | 69.7 | 0.76 (0.54–1.08) | 0.12 |
| HPyV10 (VP1) | 282 | 94.6 | 285 | 96.9 | 0.56 (0.24–1.28) | 0.17 |
| HPyV10 (VP1±TAg) | 282 | 94.6 | 286 | 97.3 | 0.49 (0.21–1.17) | 0.11 |
Abbreviations: BKV=BK virus; CI=confidence interval; HPyV6=human polyoma virus 6; HPyV7=human polyoma virus 7; HPyV10=human polyoma virus 10; JCV=JC virus; MCV=Merkel cell polyoma virus; n=number; TSV=trichodysplasia spinulosa-associated polyoma virus.
Studies included in primary analysis – Janus, NYU-WHS, SCHS, SWHS.
Seropositivity for each polyomavirus VP1 defined as MFI⩾250 and MFI⩾400 for each TAg (except for MCV small Ag where seropositivity⩾200 MFI).